# OnCo record transcend-nhl-001 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/transcend-nhl-001/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "transcend-nhl-001", "NCT02631044" ;
  schema:name "TRANSCEND NHL 001"@en ;
  schema:alternateName "JCAR017"@en, "liso-cel pivotal study"@en, "TRANSCEND NHL 001"@en ;
  schema:description "The study that registered the third CAR-T cell product for lymphoma, built from a fixed one-to-one mix of two kinds of T cell, with fewer severe immune side effects than its predecessors."@en ;
  schema:url <https://onco.cc/trials/transcend-nhl-001/> ;
  schema:dateModified "2026-10-01"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02631044>, <https://doi.org/10.1016/S0140-6736(20)31366-0> ;
  onco:status "positive" ;
  onco:tag "lymphoma-evidence" ;
  onco:phase "1" ;
  schema:startDate "2016-01-06" ;
  onco:cancers <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/> ;
  onco:technologies <https://onco.cc/technologies/car-t/> ;
  onco:targets <https://onco.cc/targets/cd19/> ;
  onco:drugs <https://onco.cc/drugs/lisocabtagene-maraleucel/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:terms <https://onco.cc/terms/crs/>, <https://onco.cc/terms/icans/>, <https://onco.cc/terms/orr/>, <https://onco.cc/terms/complete-response/>, <https://onco.cc/terms/double-hit-lymphoma/>, <https://onco.cc/terms/lymphoma-tx-car-t-pathway/> ;
  onco:trials <https://onco.cc/trials/transform/>, <https://onco.cc/trials/zuma-1/>, <https://onco.cc/trials/juliet/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/>, <https://onco.cc/bottlenecks/b-aging-comorbidity/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-transcend-nhl-001-liso-cel-lancet-2020/> .